1-1 of 1
Yoko Hasegawa
Close
Sort by
Journal Articles

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

Keiichi Sakakibara, Naoya Saito, Takuji Sato, Atsushi Suzuki, Yoko Hasegawa, Jonathan M. Friedman, Donald W. Kufe, Daniel D. VonHoff, Tadahiko Iwami, Takumi Kawabe
Journal: Blood
Blood (2011) 118 (14): 3922–3931.
https://doi.org/10.1182/blood-2011-01-333138
Published: 2011
Includes: Supplemental data